ITCI icon

Intra-Cellular Therapies

85.24 USD
+1.24
1.48%
At close Dec 24, 4:00 PM EST
After hours
85.24
+0.00
0.00%
1 day
1.48%
5 days
-2.98%
1 month
0.29%
3 months
12.87%
6 months
12.80%
Year to date
20.92%
1 year
19.58%
5 years
121.46%
10 years
373.82%
 

About: Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Employees: 561

0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

86% more call options, than puts

Call options by funds: $27.3M | Put options by funds: $14.7M

43% more funds holding in top 10

Funds holding in top 10: 7 [Q2] → 10 (+3) [Q3]

6% more repeat investments, than reductions

Existing positions increased: 132 | Existing positions reduced: 125

2% more capital invested

Capital invested by funds: $6.71B [Q2] → $6.87B (+$159M) [Q3]

4.1% less ownership

Funds ownership: 92.85% [Q2] → 88.75% (-4.1%) [Q3]

6% less funds holding

Funds holding: 370 [Q2] → 348 (-22) [Q3]

34% less first-time investments, than exits

New positions opened: 43 | Existing positions closed: 65

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$89
4%
upside
Avg. target
$98
15%
upside
High target
$108
27%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
JP Morgan
Jessica Fye
39% 1-year accuracy
16 / 41 met price target
4%upside
$89
Overweight
Maintained
4 Nov 2024
Needham
Ami Fadia
32% 1-year accuracy
49 / 154 met price target
17%upside
$100
Buy
Reiterated
31 Oct 2024
Morgan Stanley
Jeffrey Hung
35% 1-year accuracy
6 / 17 met price target
11%upside
$95
Overweight
Maintained
11 Oct 2024
RBC Capital
Brian Abrahams
14% 1-year accuracy
11 / 79 met price target
27%upside
$108
Outperform
Maintained
4 Oct 2024

Financial journalist opinion

Based on 5 articles about ITCI published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting
Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy for the treatment of major depressive disorder
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting
Positive
Seeking Alpha
2 weeks ago
Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move
CAPLYTA showed strong revenue growth, with Q3 2024 net product revenues of $125.8 million, which was a 39% year-over-year increase. Potential revenue boost if CAPLYTA's label is expanded to include it as an adjunctive therapy for major depressive disorder, addressing a significant unmet need. Lenrispodun, a PDE inhibitor, is in a phase 2 study for Parkinson's Disease, with potential data release by late 2025/early 2026, offering another blockbuster opportunity.
Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move
Positive
Zacks Investment Research
2 weeks ago
ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD
Intra-Cellular submits an sNDA to the FDA, seeking the label expansion of Caplyta to treat MDD in adults as an adjunctive therapy to antidepressants.
ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD
Neutral
GlobeNewsWire
3 weeks ago
Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy
BEDMINSTER, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced that it has recently submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for CAPLYTA (lumateperone) for the treatment of Major Depressive Disorder (MDD) in adults, as adjunctive therapy to antidepressants.
Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy
Positive
Zacks Investment Research
3 weeks ago
Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report?
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report?
Neutral
GlobeNewsWire
1 month ago
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences:
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
Neutral
GlobeNewsWire
1 month ago
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
Positive
Reuters
1 month ago
Intra-Cellular's schizophrenia drug meets main goal in late-stage trial
Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial.
Intra-Cellular's schizophrenia drug meets main goal in late-stage trial
Neutral
Seeking Alpha
1 month ago
Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Founder, Chairman and CEO Mark Neumann - EVP and CCO Sanjeev Narula - CFO Suresh Durgam - EVP and CMO Conference Call Participants Andrew Tsai - Jefferies Jessica Fye - JPMorgan Charles Duncan - Cantor Jason Gerberry - Bank of America Securities Jeff Hung - Morgan Stanley Michael DiFiore - Evercore David Amsellem - Piper Sandler Joel Beatty - Baird Corinne Johnson - Goldman Sachs Operator Good day and thank you for standing by. Welcome to Intra-Cellular Therapies 3Q 2024 Earnings Conference Call.
Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
Intra-Cellular reports mixed third-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
Charts implemented using Lightweight Charts™